Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B et al (2023) Classical Hodgkin Lymphoma: from past to Future—A Comprehensive Review of Pathophysiology and therapeutic advances. Int J Mol Sci 24(12):10095

Article  CAS  PubMed  PubMed Central  Google Scholar 

André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al (2017) Early Positron Emission Tomography response–adapted treatment in stage I and II Hodgkin Lymphoma: final results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol 35(16):1786–1794

Article  PubMed  Google Scholar 

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M et al (2016) US Intergroup Trial of Response-Adapted Therapy for stage III to IV Hodgkin Lymphoma using early interim fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34(17):2020–2027

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

Article  PubMed  Google Scholar 

Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT et al (2015) Results of a Multicenter phase II trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 21(12):2136–2140

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagpal P, Akl MR, Ayoub NM, Tomiyama T, Cousins T, Tai B et al (2016) Pediatric Hodgkin lymphoma- biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget 7(41):67551–67573

Article  PubMed  PubMed Central  Google Scholar 

Lohri A, Barnett M, Fairey R, O’Reilly S, Phillips G, Reece D et al (1991) Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77(10):2292–2298

Article  CAS  PubMed  Google Scholar 

LaCasce AS (2019) Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease. Hematol Oncol 37(S1):87–91

Article  CAS  PubMed  Google Scholar 

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J et al (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 130(20):2196–2203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochberg J, Basso J, Shi Q, Klejmont L, Flower A, Bortfeld K et al (2022) Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial. J Immunother Cancer 10(5):e004445

Article  PubMed  PubMed Central  Google Scholar 

Andreou JA, Kosmidis PA, Gouliamos AD (eds) (2016) PET/CT in Lymphomas. Springer International Publishing, Cham

Google Scholar 

Nikolaenko L, Nademanee A (2020) Brentuximab vedotin and its use in the treatment of advanced Hodgkin’s lymphoma. Future Oncol 16(29):2273–2282

Article  CAS  PubMed  Google Scholar 

Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236(1):219–242

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L et al (2019) Application of PD-1 blockade in Cancer Immunotherapy. Comput Struct Biotechnol J 17:661–674

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM et al (2022) NCCN Guidelines® insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw 20(4):322–334

Article  CAS  PubMed  Google Scholar 

Stark MC, Joubert AM, Visagie MH (2023) Molecular Farming of Pembrolizumab and Nivolumab. Int J Mol Sci 24(12):10045

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alnasser SM, Alharbi KS, Almutairy AF, Almutairi SM, Alolayan AM (2023) Autologous stem cell transplant in Hodgkin’s and Non-hodgkin’s lymphoma, multiple myeloma, and AL Amyloidosis. Cells 12(24):2855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alnasser SM (2022) Stem cell challenge in cancer progression, oncology and therapy. Gene 840:146748

Article  CAS  PubMed  Google Scholar 

Samara Y, Mei M (2022) Autologous stem cell transplantation in Hodgkin Lymphoma—latest advances in the era of Novel therapies. Cancers (Basel) 14(7):1738

Article  CAS  PubMed  Google Scholar 

National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda, MD: U.S. Department of Health and Human Services; 2017 [Internet]. [cited 2024 Dec 12]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

Ma H, Li X, Lin M, Lv K, Zhang M, Wu X (2021) Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma. Am J Transl Res 13(11):12206–12216

CAS  PubMed  PubMed Central  Google Scholar 

Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN et al (2021) Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study. Hematol Oncol 39(4):498–505

Article  CAS  PubMed  Google Scholar 

Takiar R, Karimi Y (2022) Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory classical Hodgkin’s lymphoma: so many options, how to choose? Cancers (Basel). 14(14):3526

Othman T, Herrera A, Mei M (2021) Emerging therapies in relapsed and refractory Hodgkin Lymphoma: what comes next after Brentuximab Vedotin and PD-1 inhibition? Curr Hematol Malig Rep 16(1):1–7

Article  PubMed  Google Scholar 

Makita S, Maruyama D, Tobinai K (2020) Safety and Efficacy of Brentuximab Vedotin in the treatment of Classic Hodgkin Lymphoma. Onco Targets Ther 13:5993–6009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishizawa K, Yanai T (2019) Hematopoietic stem cell transplantation and Brentuximab Vedotin for patients with relapsed or refractory Hodgkin Lymphoma and systemic anaplastic large-cell lymphoma. Adv Ther 36(10):2679–2696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M (2022) Brentuximab Vedotin and Pembrolizumab Combination in patients with Relapsed/Refractory Hodgkin Lymphoma: a single-centre retrospective analysis. Cancers (Basel) 14(4):982

Article  CAS  PubMed  Google Scholar 

Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J et al (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132(25):2639–2642

Article  CAS  PubMed  Google Scholar 

Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A et al (2020) Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 61(7):1732–1735

Article  CAS  PubMed  Google Scholar 

Kedmi M, Khaustov P, Ribakovsy E, Benjamini O, Avigdor A (2021) Outcomes related to FDG-PET-CT response in patients with Hodgkin Lymphoma treated with brentuximab-vedotin at relapse or consolidation. Clin Lymphoma Myeloma Leuk 21(12):e929–e937

Article  CAS  PubMed